Published in Int J Clin Exp Med on September 28, 2012
Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging (2013) 0.85
Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer (2014) 0.81
PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors. ScientificWorldJournal (2014) 0.81
Molecular imaging and therapy of merkel cell carcinoma. Cancers (Basel) (2014) 0.80
Nuclear medicine techniques in Merkel cell carcinoma: A case report and review of the literature. Oncol Lett (2015) 0.75
Trabecular carcinoma of the skin. Arch Dermatol (1972) 3.66
Epidermal progenitors give rise to Merkel cells during embryonic development and adult homeostasis. J Cell Biol (2009) 2.24
Trabecular carcinoma of the skin: an ultrastructural study. Cancer (1978) 1.75
Merkel cell tumour: clinical behaviour and treatment. Br J Surg (1991) 1.50
Merkel cell carcinoma: CT findings in 12 patients. AJR Am J Roentgenol (1996) 1.19
Imaging of Merkel cell carcinoma. Radiographics (2002) 1.15
Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol (2008) 1.06
Merkel cell carcinoma of the skin: imaging and clinical features in 93 cases. Br J Radiol (1996) 1.02
New immunocytochemical observations with diagnostic significance in cutaneous neuroendocrine carcinoma. Am J Dermatopathol (1984) 0.97
Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Cancer Control (2000) 0.95
The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia. J Am Acad Dermatol (2010) 0.94
Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch Dermatol (1992) 0.90
Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. Oncol Rep (2006) 0.89
Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients. J Eur Acad Dermatol Venereol (2011) 0.86
68Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma. Clin Nucl Med (2012) 0.81
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Processing of generator-produced 68Ga for medical application. J Nucl Med (2007) 2.75
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Imaging of neuroendocrine tumors. Semin Nucl Med (2006) 2.01
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging (2014) 1.92
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging (2010) 1.68
Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging (2008) 1.50
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging (2010) 1.39
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology (2012) 1.38
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm (2007) 1.23
Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imaging (2009) 1.22
Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans (2011) 1.20
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med (2011) 1.08
Automated 3-dimensional registration of stand-alone (18)F-FDG whole-body PET with CT. J Nucl Med (2003) 1.04
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2010) 1.03
Long-term follow-up of antithyroid peroxidase antibodies in patients with chronic autoimmune thyroiditis (Hashimoto's thyroiditis) treated with levothyroxine. Thyroid (2008) 1.02
[18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg (2009) 1.02
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging (2012) 1.02
EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging (2010) 1.02
Intense 18F-fluoride accumulation in liver metastases from a neuroendocrine tumor after peptide receptor radionuclide therapy. Clin Nucl Med (2012) 1.00
Bone scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 1.00
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2010) 0.99
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol (2013) 0.99
Simplified NaCl based (68)Ga concentration and labeling procedure for rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem (2012) 0.97
Stereotactic radiation treatment planning and follow-up studies involving fused multimodality imaging. J Neurosurg (2004) 0.97
[Should all patients with thyroid nodules > or = 1 cm undergo fine-needle aspiration biopsy?]. Nuklearmedizin (2009) 0.97
131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.96
PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging (2010) 0.96
Our 2014 approach to mucormycosis. Mycoses (2014) 0.96
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol (2005) 0.96
Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab (2008) 0.95
Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am (2011) 0.93
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med (2009) 0.93
Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood (2012) 0.93
Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun (2010) 0.93
A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot (2012) 0.93
FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.92
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med (2012) 0.92
67Ga scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.92
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol (2009) 0.91
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin (2016) 0.91
Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany. Oncol Res Treat (2014) 0.90
Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging (2012) 0.90
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS One (2013) 0.90
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2014) 0.89
18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma (2013) 0.89
Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology (2012) 0.89
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol (2005) 0.89
The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Recent Results Cancer Res (2013) 0.88
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.87
Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging (2011) 0.87
Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view. J Pharm Pharm Sci (2007) 0.87
EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol (2012) 0.86
Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging (2009) 0.86
Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging (2002) 0.85
Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol (2003) 0.85
Is there a need for positron emission tomography imaging to stage the N0 neck in T1-T2 squamous cell carcinoma of the oral cavity or oropharynx? Ann Otol Rhinol Laryngol (2008) 0.85
Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MSDS trial. Eur J Endocrinol (2010) 0.84
Characterization of SnO2-based (68)Ge/ (68)Ga generators and (68)Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-term constancy. EJNMMI Res (2014) 0.84
Cost estimation of thyroid disorders in Germany. Thyroid (2002) 0.84
Synthesis and structure of novel sugar-substituted bipyridine complexes of rhenium and 99m-technetium. Chemistry (2007) 0.84
Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors. Recent Results Cancer Res (2013) 0.83
Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res (2003) 0.83
Breast scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.83
A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation. Transpl Immunol (2010) 0.83
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose? Recent Results Cancer Res (2013) 0.82
Electrochemotherapy in advanced skin tumors and cutaneous metastases - a retrospective multicenter analysis. J Dtsch Dermatol Ges (2015) 0.82
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem (2011) 0.82
High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT. Recent Results Cancer Res (2013) 0.81
High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer. J Clin Oncol (2011) 0.81
Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. Int J Antimicrob Agents (2011) 0.81
68Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma. Clin Nucl Med (2012) 0.81
One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2011) 0.81
Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. Endocr Relat Cancer (2010) 0.80
Interesting image. Pancreatic neuroendocrine tumor with involvement of the inferior mesenteric vein diagnosed by Ga-68 DOTA-TATE PET/CT. Clin Nucl Med (2010) 0.80
Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma. Leuk Lymphoma (2003) 0.80
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. J Immunother (2014) 0.79
Cell death induced by 131 I in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis? Nucl Med Commun (2006) 0.79
Purification and labeling strategies for (68)Ga from (68)Ge/ (68)Ga generator eluate. Recent Results Cancer Res (2013) 0.79
Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers. Virchows Arch (2014) 0.79
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET. Lung Cancer (2012) 0.78
Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours). Eur J Nucl Med Mol Imaging (2015) 0.78
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient. Recent Results Cancer Res (2013) 0.78
Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm. Pancreas (2015) 0.78
Localization of Radiolabeled Somatostatin Analogs in the Spleen. Clin Nucl Med (2016) 0.78
Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Recent Results Cancer Res (2013) 0.78
[18F]Fluorodeoxyglucose positron emission tomography/computed tomography-positive gastric adenocarcinoma in a 12-year-old girl with Peutz-Jeghers syndrome. J Clin Oncol (2012) 0.78
[Surgical therapy for pulmonary metastases from malignant melanoma]. Hautarzt (2015) 0.77
Stability of radioactive colloids for radiation synovectomy: influence of X-ray contrast agents, anaesthetics and glucocorticoids in vitro. Nucl Med Commun (2005) 0.77
Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma. Leuk Lymphoma (2010) 0.77
Successful treatment of metastasized pancreatic vasoactive intestinal polypeptide-secreting tumor unresponsive to high-dose octreotide by peptide receptor radionuclide therapy using 90Y DOTATATE. Clin Nucl Med (2013) 0.77
Synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine based on a cartridge purification method. Nucl Med Biol (2011) 0.76